Testing a new immunosuppressant to replace kidney-damaging drugs after transplant

After a kidney transplant, patients typically take medications called calcineurin inhibitors to prevent rejection—but these drugs can damage the kidney over time. This trial is testing whether belatacept, a different type of immunosuppressant, can replace those damaging drugs between 3 and 12 months after transplant in people whose new kidney isn't functioning as well as hoped. The goal is to protect your transplanted kidney from long-term damage while still preventing rejection.

Standard anti-rejection medications have saved countless transplants, but they ironically cause slow damage to the kidney over years, leading many patients to eventually return to dialysis. This medication works differently and showed better long-term kidney function and survival in previous research, but it has not yet become a standard option for patients with early graft problems.